Russian Pharmaceutical Industry Leader
03.06.2020
JSC Pharmasyntez took part in the “High-Tech Medical Care in the 21st Century Gynecology: Expert View” Online Conference
JSC Pharmasyntez took part in the “High-Tech Medical Care in the 21st Century Gynecology: Expert View” Online Conference

At the conference, Mikhail Shurygin, Chief R&D Officer of Pharmasyntez, presented results of the research of abdominal adhesions and clinical trial results on the innovative drug Seroguard® (INN: Adezmapimod).

“The candidate drug (Seroguard®) is the world’s first pharmacological agent for the prevention of adhesions with the effect on intracellular signaling cascades and is currently the only one inhibiting delayed formation of post-surgery adhesions. The results of phase I-II clinical trials have shown that the drug has a good safety and tolerability profile and significantly inhibits post-surgery adhesion formation”, Mikhail Shurygin said.

Leyla Adamyan, Chief obstetrician-gynecologist of the Russian Federation, appreciated Pharmasyntez’s contribution to the healthcare system and noted that, besides candidate drug development, the company would soon present a range of hormonal drugs, oral contraceptives and endocrine medications. 

Earlier, the World Health Organization has granted an international nonproprietary name to the pharmaceutical substance of Seroguard®.